KR102408525B1 - 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자 - Google Patents

화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자 Download PDF

Info

Publication number
KR102408525B1
KR102408525B1 KR1020187022622A KR20187022622A KR102408525B1 KR 102408525 B1 KR102408525 B1 KR 102408525B1 KR 1020187022622 A KR1020187022622 A KR 1020187022622A KR 20187022622 A KR20187022622 A KR 20187022622A KR 102408525 B1 KR102408525 B1 KR 102408525B1
Authority
KR
South Korea
Prior art keywords
delete delete
drug
cancer
irinotecan
drug carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187022622A
Other languages
English (en)
Korean (ko)
Other versions
KR20180094112A (ko
Inventor
안드레 이 넬
환 멍
샹성 류
Original Assignee
더 리전트 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전트 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리전트 오브 더 유니버시티 오브 캘리포니아
Priority to KR1020227019372A priority Critical patent/KR20220085840A/ko
Publication of KR20180094112A publication Critical patent/KR20180094112A/ko
Application granted granted Critical
Publication of KR102408525B1 publication Critical patent/KR102408525B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paints Or Removers (AREA)
KR1020187022622A 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자 Active KR102408525B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227019372A KR20220085840A (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276634P 2016-01-08 2016-01-08
US62/276,634 2016-01-08
PCT/US2017/012625 WO2017120537A1 (en) 2016-01-08 2017-01-06 Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019372A Division KR20220085840A (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자

Publications (2)

Publication Number Publication Date
KR20180094112A KR20180094112A (ko) 2018-08-22
KR102408525B1 true KR102408525B1 (ko) 2022-06-13

Family

ID=59274072

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247013856A Ceased KR20240064009A (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자
KR1020187022622A Active KR102408525B1 (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자
KR1020227019372A Ceased KR20220085840A (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247013856A Ceased KR20240064009A (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227019372A Ceased KR20220085840A (ko) 2016-01-08 2017-01-06 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자

Country Status (8)

Country Link
US (5) US10143660B2 (enExample)
EP (2) EP4218739A3 (enExample)
JP (2) JP7068173B2 (enExample)
KR (3) KR20240064009A (enExample)
CN (1) CN108601746B (enExample)
AU (3) AU2017206077B2 (enExample)
CA (1) CA3010711A1 (enExample)
WO (1) WO2017120537A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12329805B2 (en) 2017-03-09 2025-06-17 Diamedica Inc. Dosage forms of tissue kallikrein 1

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2964201B1 (en) 2013-03-05 2024-02-14 The Regents of the University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
EP3270932B1 (en) 2015-03-16 2024-08-21 PDX Pharmaceuticals, Inc. Cross-linked polymer modified nanoparticles
EP4218739A3 (en) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
EP3464275B1 (en) 2016-05-26 2024-05-08 Recurium IP Holdings, LLC Egfr inhibitor compounds
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
US12383499B2 (en) 2018-01-01 2025-08-12 The Regents Of The University Of California Scale up synthesis of silicasome nanocarriers
CN108562737A (zh) * 2018-01-12 2018-09-21 天津大学 用阳离子脂质体包裹负载钙黄绿素的介孔二氧化硅纳米颗粒的制备方法
WO2019161325A1 (en) * 2018-02-19 2019-08-22 Boise State University Radiation-triggered liposomes
US20210007999A1 (en) * 2018-03-02 2021-01-14 January Therapeutics, Inc. Nanoparticle compositions
AU2019261329B2 (en) * 2018-04-23 2024-09-05 Inspirmed Corp. Inhalable liposomal sustained release composition for use in treating pulmonary diseases
EP3849523A4 (en) * 2018-09-10 2022-06-08 Taiwan Liposome Company, Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
AU2019360164B2 (en) 2018-10-16 2024-12-19 Pharma In Silica Laboratories Inc. Tunable process for silica capsules/spheres preparation and their use
JP7477844B2 (ja) * 2018-10-17 2024-05-02 タイワン リポソーム カンパニー リミテッド 免疫調節剤を含む徐放性医薬組成物およびその使用
CN109557158B (zh) * 2018-12-12 2020-12-08 郑州大学 酶固定基质在有机磷杀虫剂生物检测领域中的应用
US12351653B1 (en) 2019-03-08 2025-07-08 Lisata Therapeutics, Inc. Pharmaceutical compositions comprising novel cyclic peptides
GB201904337D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904336D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904338D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd Fluorouracil-containing formulations
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
EP4005583A4 (en) * 2019-04-01 2023-04-26 Industry - University Cooperation Foundation Hanyang University CP2C TARGETING PEPTIDE ANTICANCER AGENT
EP3972572A4 (en) * 2019-05-20 2023-11-22 Board Of Regents Of the University Of Texas System Formulations of cyclic macromolecule-based nanoparticles encapsulating small molecules
AU2020313914A1 (en) * 2019-07-12 2022-01-20 Oregon Health & Science University Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US20220249389A1 (en) 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
CN110548029B (zh) * 2019-10-09 2022-08-16 上海交通大学医学院 甲磺酸奥希替尼在制备治疗真菌感染药物中的应用
CN111074282B (zh) * 2019-10-15 2021-11-05 东营施普瑞石油工程技术有限公司 一种pH响应型可降解智能缓蚀剂、制备方法及其应用
CN110559280B (zh) * 2019-10-16 2021-06-25 中国人民解放军军事科学院军事医学研究院 治疗肺癌的载紫杉醇脂质体细菌吸入制剂
AU2021266721A1 (en) * 2020-05-04 2022-12-08 Lisata Therapeutics Australia Pty Ltd. Methods for treating pancreatic cancer and other solid tumors
WO2021226368A1 (en) * 2020-05-06 2021-11-11 Nanotech Pharma Inc. Liposome formulations for treatment of cancers and drug resistance of cancers
WO2022006083A1 (en) * 2020-06-30 2022-01-06 The Regents Of The University Of California Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic
WO2022115075A1 (en) * 2020-11-30 2022-06-02 Ege Üni̇versi̇tesi̇ Targeted nanoparticles carrying dual drugs in the treatment of melanoma
US20240032535A1 (en) * 2020-12-14 2024-02-01 Bps Just Energy Technology, Llc Antimicrobial compositions and methods with supramolecular structures
US20220378711A1 (en) * 2021-05-11 2022-12-01 United States Government As Represented By The Department Of Veterans Affairs PH-Responsive Nanoparticles for Treating Cancer
CN113521035B (zh) * 2021-08-05 2023-04-25 河南大学 化学免疫联合治疗纳米药物的制备方法及应用
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法
WO2023064887A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The University Of Illinois Mechanochemical dynamic therapy for focal cancer treatment
CN114487083B (zh) * 2022-01-19 2024-05-07 中国地质大学（北京） 一种磁性羟基纳米材料Fe3O4@COFs及其在磺胺质谱检测领域的应用
CN114796055B (zh) * 2022-05-19 2023-08-15 广东艾粒生物科技有限责任公司 富含脂质体纳米粒的美白敷料及其制备方法
WO2024035784A1 (en) * 2022-08-10 2024-02-15 Auburn University Shrinking nanomaterial for biomedical applications
WO2024050310A1 (en) * 2022-08-29 2024-03-07 Sorrento Therapeutics, Inc. Lipid-coated nanoparticles
CN115636885B (zh) * 2022-10-26 2023-08-11 湖北中医药大学 一种季铵环糊精及其制备方法和应用、银纳米粒子环糊精复合物及其制备方法和应用
EP4364726A1 (en) * 2022-11-02 2024-05-08 Nano Targeting & Therapy Biopharma Inc. Method for treating a cancer and/or cancer metastasis
WO2024148364A1 (en) * 2023-01-08 2024-07-11 Attivare Therapeutics Inc. Intertumoral and intratumoral delivery of cytokines using mesoporous silica rods as an immunomodulating system
WO2024216145A1 (en) * 2023-04-13 2024-10-17 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor
KR102666470B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
KR102666469B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
IT202300015396A1 (it) * 2023-07-21 2025-01-21 Torino Politecnico Nanoparticelle rivestite e loro uso per il trasporto di agenti terapeutici e diagnostici
US12102693B1 (en) * 2023-08-25 2024-10-01 Nanomedtrix, Llc Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model
KR102647264B1 (ko) * 2023-11-01 2024-03-14 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
WO2025100777A1 (ko) * 2023-11-08 2025-05-15 주식회사 엔테라퓨틱스 표면이 개질된 나노입자 및 이의 약물 전달 용도
WO2025179264A1 (en) * 2024-02-22 2025-08-28 President And Fellows Of Harvard College Functionalized silica nanoparticles and methods of making and using the same
CN119236105B (zh) * 2024-09-29 2025-09-05 中南大学 一种基于铜死亡的多功能抗肿瘤纳米药物递送系统及其制备方法与应用
US12390420B1 (en) 2024-10-22 2025-08-19 Bryet Us, Inc. Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE4217353B4 (de) 1992-05-26 2008-02-21 Nimbus Biotechnologie Gmbh Verfahren zur säulenchromatographischen Trennung von Proteinen mittels Lipidbilayer-beschichteter Silicagele
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
DE19814775C2 (de) 1998-04-02 2001-04-19 Nimbus Biotechnologie Gmbh Verfahren zur Bestimmung der Lipid-Bindungskonstanten von Substanzen in wässriger Lösung an Oberflächen aus amphiphilen Molekülen
US7618565B2 (en) 2001-08-16 2009-11-17 Polytechnic Institute Of New York University Lipobeads and their production
US20040005352A1 (en) 2002-04-16 2004-01-08 Lopez Gabriel P. Biologically functionalized porous microspheres
WO2004017944A1 (en) 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
ES2967961T3 (es) * 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomas útiles en la administración de fármacos
US20080305341A1 (en) 2004-08-03 2008-12-11 Waldfried Plieth Process for Coating Metallic Surfaces With an Anti-Corrosive Coating
WO2006032136A1 (en) 2004-09-20 2006-03-30 British Columbia Cancer Agency Branch Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
US20110104073A1 (en) 2007-01-18 2011-05-05 Qi Zeng Iron/Iron Oxide Nanoparticle and Use Thereof
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20100284924A1 (en) 2008-01-23 2010-11-11 The Regents Of The University Of California Nano-devices having impellers for capture and release of molecules
US20100310465A1 (en) 2008-01-23 2010-12-09 The Regents Of The University Of California Nano-devices having releasable seals for controlled release of molecules
WO2010071831A2 (en) 2008-12-19 2010-06-24 The Regents Of The University Of California Structured silver-mesoporous silica nanoparticles having antimicrobial activity
US8734816B2 (en) 2009-01-05 2014-05-27 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
US8992984B1 (en) * 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
TWI383808B (zh) 2009-11-23 2013-02-01 Nat Univ Tsing Hua 磷脂質包覆中孔洞二氧化矽奈米球的合成與其生醫應用
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
WO2012009448A2 (en) 2010-07-13 2012-01-19 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
US9532949B2 (en) 2011-07-19 2017-01-03 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
AU2012323937A1 (en) * 2011-10-14 2014-06-05 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US20140138278A1 (en) 2012-11-20 2014-05-22 Mpt, Inc. Advertising Media for Application to Packaging Materials
EP2964201B1 (en) 2013-03-05 2024-02-14 The Regents of the University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
EP3270932B1 (en) 2015-03-16 2024-08-21 PDX Pharmaceuticals, Inc. Cross-linked polymer modified nanoparticles
LU92784B1 (en) 2015-07-22 2017-01-31 Luxembourg Inst Of Science And Tech (List) Negatively charged self-assembling supported lipid bilayer on mesoporous silica nanoparticles, method of synthesis and use as a nanovector
EP4218739A3 (en) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
US12383499B2 (en) 2018-01-01 2025-08-12 The Regents Of The University Of California Scale up synthesis of silicasome nanocarriers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research, 2006, 66(6), pp.3271-3277*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12329805B2 (en) 2017-03-09 2025-06-17 Diamedica Inc. Dosage forms of tissue kallikrein 1

Also Published As

Publication number Publication date
AU2023233055A1 (en) 2023-10-05
JP2022105089A (ja) 2022-07-12
JP7636805B2 (ja) 2025-02-27
US20200383929A1 (en) 2020-12-10
US20220160644A1 (en) 2022-05-26
US20190160015A1 (en) 2019-05-30
US20250281417A1 (en) 2025-09-11
KR20220085840A (ko) 2022-06-22
WO2017120537A1 (en) 2017-07-13
CN108601746A (zh) 2018-09-28
AU2017206077B2 (en) 2021-11-18
US12171884B2 (en) 2024-12-24
CN108601746B (zh) 2024-09-13
CA3010711A1 (en) 2017-07-13
EP3399966A4 (en) 2019-09-04
KR20240064009A (ko) 2024-05-10
AU2023233055B2 (en) 2025-07-03
US10765636B2 (en) 2020-09-08
US10143660B2 (en) 2018-12-04
EP4218739A3 (en) 2023-08-09
EP4218739A2 (en) 2023-08-02
AU2017206077A1 (en) 2018-07-05
JP2019501198A (ja) 2019-01-17
AU2022200881A1 (en) 2022-03-10
JP7068173B2 (ja) 2022-05-16
KR20180094112A (ko) 2018-08-22
AU2022200881B2 (en) 2023-10-12
US11096900B2 (en) 2021-08-24
EP3399966B1 (en) 2023-03-29
EP3399966A1 (en) 2018-11-14
US20180098945A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP7636805B2 (ja) カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子
Ismail et al. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma
Liu et al. Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer
Malhotra et al. Red blood cells membrane‐derived nanoparticles: applications and key challenges in their clinical translation
Guimarães et al. Nanoparticles for immune cytokine TRAIL-based cancer therapy
Zhao et al. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer
US12383499B2 (en) Scale up synthesis of silicasome nanocarriers
Shi et al. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo
JP2018533628A (ja) エキノマイシン製剤、その製造法および使用法
US20240245721A1 (en) Double sided chimeric antigen receptor (car) engineered cell membrane based drug delivery systems
Hajimolaali et al. Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
Hunt Precision targeting of intraperitoneal tumors with peptideguided nanocarriers
Lúcio et al. Functional lipid nanosystems in cancer
EP4489793A1 (en) A drug nanocarrier system to deliver a combination of tlr agonists and/or a lipoxin plus immunogenic cell death inducing chemotherapeutic agents for cancer immunotherapy
HK1261293B (zh) 用於运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
HK1261293A1 (en) Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
Yao et al. A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy
Detampel Targeting of hepatocytes Using vector-conjugated liposomes: evaluation of targeting strategies
HK1190632A (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180806

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210518

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220308

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220608

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220609

End annual number: 3

Start annual number: 1

PG1601 Publication of registration